{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T11:37:36Z","timestamp":1791632256241,"version":"4.3.4"},"reference-count":84,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Fundacion CardioInfantil IC and Universidad del Rosario"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Glucagon-like peptide-1 receptor agonists, originally developed for the treatment of metabolic disorders, have recently emerged as promising candidates for the management of substance use disorders. This review synthesizes preclinical, clinical, and translational evidence on the effects of glucagon-like peptide-1 receptor agonists across addiction models involving alcohol, nicotine, psychostimulants, and opioids. In animal studies, glucagon-like peptide-1 receptor agonists consistently reduce drug intake, attenuate dopamine release in reward circuits, and decrease relapse-like behavior. Clinical and observational studies provide preliminary support for these findings, particularly among individuals with comorbid obesity or insulin resistance. However, several translational barriers remain, including limited blood\u2013brain barrier penetration, species differences in pharmacokinetics, and variability in treatment response due to genetic and metabolic factors. Ethical considerations and methodological heterogeneity further complicate clinical translation. Future directions include the development of central nervous system penetrant analogues, personalized medicine approaches incorporating pharmacogenomics, and rigorously designed trials in diverse populations. Glucagon-like peptide-1 receptor agonists may offer a novel therapeutic strategy that addresses both metabolic and neuropsychiatric dimensions of addiction, warranting further investigation to define their role in the evolving landscape of substance use disorder treatment.<\/jats:p>","DOI":"10.3390\/ijms26115338","type":"journal-article","created":{"date-parts":[[2025,6,2]],"date-time":"2025-06-02T11:40:32Z","timestamp":1748864432000},"page":"5338","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":43,"title":["GLP-1 Analogues in the Neurobiology of Addiction: Translational Insights and Therapeutic Perspectives"],"prefix":"10.3390","volume":"26","author":[{"given":"Juan David","family":"Marquez-Meneses","sequence":"first","affiliation":[{"name":"Pharmacology Unit, Department of Biomedical Sciences, School of Medicine and Health Sciences, Universidad del Rosario, Bogota 111221, Colombia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Santiago Arturo","family":"Olaya-Bonilla","sequence":"additional","affiliation":[{"name":"Pharmacology Unit, Department of Biomedical Sciences, School of Medicine and Health Sciences, Universidad del Rosario, Bogota 111221, Colombia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel","family":"Barrera-Carre\u00f1o","sequence":"additional","affiliation":[{"name":"Pharmacology Unit, Department of Biomedical Sciences, School of Medicine and Health Sciences, Universidad del Rosario, Bogota 111221, Colombia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-0427-2559","authenticated-orcid":false,"given":"Luc\u00eda Catalina","family":"Tibaduiza-Ar\u00e9valo","sequence":"additional","affiliation":[{"name":"Pharmacology Unit, Department of Biomedical Sciences, School of Medicine and Health Sciences, Universidad del Rosario, Bogota 111221, Colombia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Forero-C\u00e1rdenas","sequence":"additional","affiliation":[{"name":"Research Group in Applied Biomedical Sciences (UR Biomed), School of Medicine and Health Sciences, Universidad del Rosario, Bogota 111221, Colombia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liliana","family":"Carrillo-Vaca","sequence":"additional","affiliation":[{"name":"ZONAMEDICA MR S.A.S., Av Kra. 45 No 105-21, Bogota 110111, Colombia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9989-6980","authenticated-orcid":false,"given":"Luis Carlos","family":"Rojas-Rodr\u00edguez","sequence":"additional","affiliation":[{"name":"Pharmacology Unit, Department of Biomedical Sciences, School of Medicine and Health Sciences, Universidad del Rosario, Bogota 111221, Colombia"},{"name":"Research Group in Applied Biomedical Sciences (UR Biomed), School of Medicine and Health Sciences, Universidad del Rosario, Bogota 111221, Colombia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7305-8727","authenticated-orcid":false,"given":"Carlos Alberto","family":"Calderon-Ospina","sequence":"additional","affiliation":[{"name":"Pharmacology Unit, Department of Biomedical Sciences, School of Medicine and Health Sciences, Universidad del Rosario, Bogota 111221, Colombia"},{"name":"Research Group in Applied Biomedical Sciences (UR Biomed), School of Medicine and Health Sciences, Universidad del Rosario, Bogota 111221, Colombia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8100-7340","authenticated-orcid":false,"given":"Jes\u00fas","family":"Rodr\u00edguez-Quintana","sequence":"additional","affiliation":[{"name":"Fundacion CardioInfantil-Instituto de Cardiolog\u00eda, Bogota 111156, Colombia"},{"name":"Hospital Universitario Mayor Mederi, Bogota 111411, Colombia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,6,1]]},"reference":[{"key":"ref_1","unstructured":"(2025, April 15). Diagnostic and Statistical Manual of Mental Disorders. Psychiatry Online. DSM Library. Available online: https:\/\/psychiatryonline.org\/doi\/book\/10.1176\/appi.books.9780890425596."},{"key":"ref_2","first-page":"349","article-title":"Limitations of DSM-5 Diagnostic Criteria for Substance Use Disorder in Adolescents: What Have We Learned after Using These Criteria for Several Years?","volume":"43","author":"Andrade","year":"2020","journal-title":"Braz. J. Psychiatry"},{"key":"ref_3","unstructured":"(2025, April 15). Cada A\u00f1o Fallecen m\u00e1s de Tres Millones de Personas, Sobre todo Varones, Debido al Consumo de Alcohol y Drogas. Available online: https:\/\/www.who.int\/es\/news\/item\/25-06-2024-over-3-million-annual-deaths-due-to-alcohol-and-drug-use-majority-among-men."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1037\/ccp0000552","article-title":"Long-Term Efficacy of Contingency Management Treatment Based on Objective Indicators of Abstinence From Illicit Substance Use up to 1 Year Following Treatment: A Meta-Analysis","volume":"89","author":"Ginley","year":"2021","journal-title":"J. Consult. Clin. Psychol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"108242","DOI":"10.1016\/j.addbeh.2024.108242","article-title":"Pharmacological Treatment for Substance Use Disorder: A Systematic Review","volume":"163","year":"2025","journal-title":"Addict. Behav."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"114622","DOI":"10.1016\/j.physbeh.2024.114622","article-title":"Glucagon-like Peptide 1 Agonist and Effects on Reward Behaviour: A Systematic Review","volume":"283","author":"Badulescu","year":"2024","journal-title":"Physiol. Behav."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s11481-021-10022-7","article-title":"Drugs and Bugs: The Gut-Brain Axis and Substance Use Disorders","volume":"17","author":"Simpson","year":"2022","journal-title":"J. Neuroimmune Pharmacol."},{"key":"ref_8","first-page":"1","article-title":"Glucagon-like Peptide-1 Receptor: Mechanisms and Advances in Therapy","volume":"9","author":"Zheng","year":"2024","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"S70","DOI":"10.2337\/db06-S020","article-title":"Glucagon-Like Peptide 1 Secretion by the L-Cell: The View From Within","volume":"55","author":"Lim","year":"2006","journal-title":"Diabetes"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1053\/j.gastro.2007.03.054","article-title":"Biology of Incretins: GLP-1 and GIP","volume":"132","author":"Baggio","year":"2007","journal-title":"Gastroenterology"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"RP97854","DOI":"10.7554\/eLife.97854","article-title":"Mechano-Regulation of GLP-1 Production by Piezo1 in Intestinal L Cells","volume":"13","author":"Huang","year":"2024","journal-title":"eLife"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1111\/bph.15576","article-title":"The role of nucleus of the solitary tract glucagon-like peptide-1 and prolactin-releasing peptide neurons in stress: Anatomy, physiology and cellular interactions","volume":"179","author":"Holt","year":"2022","journal-title":"Br. J. Pharmacol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"21","DOI":"10.2337\/db18-0729","article-title":"Preproglucagon Neurons in the Nucleus of the Solitary Tract Are the Main Source of Brain GLP-1, Mediate Stress-Induced Hypophagia, and Limit Unusually Large Intakes of Food","volume":"68","author":"Holt","year":"2019","journal-title":"Diabetes"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1210\/en.2011-1443","article-title":"GLP-1 Neurons in the Nucleus of the Solitary Tract Project Directly to the Ventral Tegmental Area and Nucleus Accumbens to Control for Food Intake","volume":"153","author":"Alhadeff","year":"2012","journal-title":"Endocrinology"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1124\/pr.115.011395","article-title":"Glucagon-Like Peptide-1 and Its Class B G Protein-Coupled Receptors: A Long March to Therapeutic Successes","volume":"68","author":"Donnelly","year":"2016","journal-title":"Pharmacol. Rev."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1111\/bph.15638","article-title":"Brain GLP-1 and the Regulation of Food Intake: GLP-1 Action in the Brain and Its Implications for GLP-1 Receptor Agonists in Obesity Treatment","volume":"179","author":"Trapp","year":"2022","journal-title":"Br. J. Pharmacol."},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Singh, I., Wang, L., Xia, B., Liu, J., Tahiri, A., El Ouaamari, A., Wheeler, M.B., and Pang, Z.P. (2022). Activation of Arcuate Nucleus Glucagon-like Peptide-1 Receptor-Expressing Neurons Suppresses Food Intake. Cell Biosci., 12.","DOI":"10.1186\/s13578-022-00914-3"},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Diz-Chaves, Y., Herrera-P\u00e9rez, S., Gonz\u00e1lez-Mat\u00edas, L.C., Lamas, J.A., and Mallo, F. (2020). Glucagon-Like Peptide-1 (GLP-1) in the Integration of Neural and Endocrine Responses to Stress. Nutrients, 12.","DOI":"10.3390\/nu12113304"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"101351","DOI":"10.1016\/j.molmet.2021.101351","article-title":"GLP-1 Physiology Informs the Pharmacotherapy of Obesity","volume":"57","author":"Drucker","year":"2022","journal-title":"Mol. Metab."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Eren-Yazicioglu, C.Y., Yigit, A., Dogruoz, R.E., and Yapici-Eser, H. (2021). Can GLP-1 Be a Target for Reward System Related Disorders? A Qualitative Synthesis and Systematic Review Analysis of Studies on Palatable Food, Drugs of Abuse, and Alcohol. Front. Behav. Neurosci., 14.","DOI":"10.3389\/fnbeh.2020.614884"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.cobeha.2016.02.005","article-title":"GLP-1 Influences Food and Drug Reward","volume":"9","author":"Hayes","year":"2016","journal-title":"Curr. Opin. Behav. Sci."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.physbeh.2012.02.017","article-title":"Neuronal and Intracellular Signaling Pathways Mediating GLP-1 Energy Balance and Glycemic Effects","volume":"106","author":"Hayes","year":"2012","journal-title":"Physiol. Behav."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"3371","DOI":"10.1016\/j.celrep.2019.05.055","article-title":"Distinct Neural Sites of GLP-1R Expression Mediate Physiological versus Pharmacological Control of Incretin Action","volume":"27","author":"Varin","year":"2019","journal-title":"Cell Rep."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"112040","DOI":"10.1016\/j.isci.2025.112040","article-title":"From the Pancreas to the Amygdala: New Brain Area Critical for Ingestive and Motivated Behavior Control Exerted by Amylin","volume":"28","author":"Byun","year":"2025","journal-title":"iScience"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"114236","DOI":"10.1016\/j.physbeh.2023.114236","article-title":"Metabolic Hormone Action in the VTA: Reward-Directed Behavior and Mechanistic Insights","volume":"268","author":"Geisler","year":"2023","journal-title":"Physiol. Behav."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"E1314","DOI":"10.1152\/ajpendo.00137.2013","article-title":"Nucleus Accumbens GLP-1 Receptors Influence Meal Size and Palatability","volume":"304","author":"Dossat","year":"2013","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1111\/adb.12583","article-title":"Activation of Glucagon-like Peptide-1 Receptors in the Nucleus Accumbens Attenuates Cocaine Seeking in Rats","volume":"24","author":"Hernandez","year":"2019","journal-title":"Addict. Biol."},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Zeng, N., Cutts, E.J., Lopez, C.B., Kaur, S., Duran, M., Virkus, S.A., and Hardaway, J.A. (2021). Anatomical and Functional Characterization of Central Amygdala Glucagon-Like Peptide 1 Receptor Expressing Neurons. Front. Behav. Neurosci., 15.","DOI":"10.3389\/fnbeh.2021.724030"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1038\/npp.2014.175","article-title":"Hippocampal GLP-1 Receptors Influence Food Intake, Meal Size, and Effort-Based Responding for Food through Volume Transmission","volume":"40","author":"Hsu","year":"2015","journal-title":"Neuropsychopharmacology"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.physbeh.2017.03.019","article-title":"Central GLP-1 Receptor Activation Modulates Cocaine-Evoked Phasic Dopamine Signaling in the Nucleus Accumbens Core","volume":"176","author":"Fortin","year":"2017","journal-title":"Physiol. Behav."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"e70004","DOI":"10.1111\/bcpt.70004","article-title":"Effects of GLP-1 Receptor Agonists in Alcohol Use Disorder","volume":"136","author":"Klausen","year":"2025","journal-title":"Basic Clin. Pharmacol. Toxicol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"e170671","DOI":"10.1172\/jci.insight.170671","article-title":"The Glucagon-like Peptide-1 (GLP-1) Analogue Semaglutide Reduces Alcohol Drinking and Modulates Central GABA Neurotransmission","volume":"8","author":"Chuong","year":"2023","journal-title":"JCI Insight"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1007\/s12264-022-00826-9","article-title":"Signaling Mechanism for Modulation by GLP-1 and Exendin-4 of GABA Receptors on Rat Retinal Ganglion Cells","volume":"38","author":"Zhang","year":"2022","journal-title":"Neurosci. Bull."},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Wang, X.-Y., Liu, Y., Cao, L.-X., Li, Y.-Z., Wan, P., and Qiu, D.-L. (2023). Glucagon-like Peptide-1 Facilitates Cerebellar Parallel Fiber Glutamate Release through PKA Signaling in Mice in Vitro. Sci. Rep., 13.","DOI":"10.1038\/s41598-023-34070-6"},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Dragonieri, S., Portacci, A., Quaranta, V.N., Carratu, P., Lazar, Z., Carpagnano, G.E., and Bikov, A. (2024). Therapeutic Potential of Glucagon-like Peptide-1 Receptor Agonists in Obstructive Sleep Apnea Syndrome Management: A Narrative Review. Diseases, 12.","DOI":"10.3390\/diseases12090224"},{"key":"ref_36","unstructured":"(2025, April 25). Pathogenesis of Sleep-Disordered Breathing in the Setting of Opioid Use: A Multiple Mediation Analysis Using Physiology. SLEEP. Oxford Academic. Available online: https:\/\/academic.oup.com\/sleep\/article\/47\/11\/zsae090\/7644414."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.sleep.2017.12.005","article-title":"Alcohol and the Risk of Sleep Apnoea: A Systematic Review and Meta-Analysis","volume":"42","author":"Simou","year":"2018","journal-title":"Sleep Med."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/s41386-019-0465-x","article-title":"Drugs, Sleep, and the Addicted Brain","volume":"45","author":"Valentino","year":"2020","journal-title":"Neuropsychopharmacology"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1037\/amp0000059","article-title":"Liking, Wanting, and the Incentive-Sensitization Theory of Addiction","volume":"71","author":"Berridge","year":"2016","journal-title":"Am. Psychol."},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Egecioglu, E., Engel, J.A., and Jerlhag, E. (2013). The Glucagon-Like Peptide 1 Analogue Exendin-4 Attenuates the Nicotine-Induced Locomotor Stimulation, Accumbal Dopamine Release, Conditioned Place Preference as Well as the Expression of Locomotor Sensitization in Mice. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0077284"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1111\/bph.15677","article-title":"The Role of Glucagon-like Peptide 1 (GLP-1) in Addictive Disorders","volume":"179","author":"Klausen","year":"2022","journal-title":"Br. J. Pharmacol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1097\/FBP.0000000000000609","article-title":"Glucagon-like Peptide-1 Receptor Agonist, Exendin-4, Reduces Reinstatement of Heroin-Seeking Behavior in Rats","volume":"32","author":"Douton","year":"2021","journal-title":"Behav. Pharmacol."},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Zhu, C., Li, H., Kong, X., Wang, Y., Sun, T., and Wang, F. (2022). Possible Mechanisms Underlying the Effects of Glucagon-Like Peptide-1 Receptor Agonist on Cocaine Use Disorder. Front. Pharmacol., 13.","DOI":"10.3389\/fphar.2022.819470"},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Shirazi, R.H., Dickson, S.L., and Skibicka, K.P. (2013). Gut Peptide GLP-1 and Its Analogue, Exendin-4, Decrease Alcohol Intake and Reward. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0061965"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1016\/j.psyneuen.2012.11.009","article-title":"The Glucagon-like Peptide 1 Analogue Exendin-4 Attenuates Alcohol Mediated Behaviors in Rodents","volume":"38","author":"Egecioglu","year":"2013","journal-title":"Psychoneuroendocrinology"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.neuropharm.2019.02.020","article-title":"Glucagon-like Peptide-1 Receptors within the Nucleus of the Solitary Tract Regulate Alcohol-Mediated Behaviors in Rodents","volume":"149","author":"Vestlund","year":"2019","journal-title":"Neuropharmacology"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.psyneuen.2019.02.006","article-title":"Brain Region Specific Glucagon-like Peptide-1 Receptors Regulate Alcohol-Induced Behaviors in Rodents","volume":"103","author":"Kalafateli","year":"2019","journal-title":"Psychoneuroendocrinology"},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Colvin, K.J., Killen, H.S., Kanter, M.J., Halperin, M.C., Engel, L., and Currie, P.J. (2020). Brain Site-Specific Inhibitory Effects of the GLP-1 Analogue Exendin-4 on Alcohol Intake and Operant Responding for Palatable Food. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21249710"},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"Aran\u00e4s, C., Edvardsson, C.E., Shevchouk, O.T., Zhang, Q., Witley, S., Sk\u00f6ldheden, S.B., Zentveld, L., Vall\u00f6f, D., Tufvesson-Alm, M., and Jerlhag, E. (2023). Semaglutide Reduces Alcohol Intake and Relapse-like Drinking in Male and Female Rats. eBioMedicine, 93.","DOI":"10.1016\/j.ebiom.2023.104642"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1038\/nn.4540","article-title":"GLP-1 Acts on Habenular Avoidance Circuits to Control Nicotine Intake","volume":"20","author":"Tuesta","year":"2017","journal-title":"Nat. Neurosci."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1007\/s00213-023-06376-w","article-title":"Liraglutide Attenuates Nicotine Self-Administration as Well as Nicotine Seeking and Hyperphagia during Withdrawal in Male and Female Rats","volume":"240","author":"Herman","year":"2023","journal-title":"Psychopharmacology"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1016\/j.physbeh.2012.03.014","article-title":"Exendin-4 Decreases Amphetamine-Induced Locomotor Activity","volume":"106","author":"Erreger","year":"2012","journal-title":"Physiol. Behav."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1038\/mp.2012.141","article-title":"GLP-1 Analog Attenuates Cocaine Reward","volume":"18","author":"Graham","year":"2013","journal-title":"Mol. Psychiatry"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.1038\/npp.2015.47","article-title":"Septal Glucagon-Like Peptide 1 Receptor Expression Determines Suppression of Cocaine-Induced Behavior","volume":"40","author":"Harasta","year":"2015","journal-title":"Neuropsychopharmacology"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"e809","DOI":"10.1038\/tp.2016.86","article-title":"Glucagon-like Peptide 1 Receptor Activation Regulates Cocaine Actions and Dopamine Homeostasis in the Lateral Septum by Decreasing Arachidonic Acid Levels","volume":"6","author":"Reddy","year":"2016","journal-title":"Transl. Psychiatry"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.1038\/npp.2015.362","article-title":"Glucagon-Like Peptide-1 Receptor Activation in the Ventral Tegmental Area Decreases the Reinforcing Efficacy of Cocaine","volume":"41","author":"Schmidt","year":"2016","journal-title":"Neuropsychopharmacology"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.physbeh.2016.04.013","article-title":"Central & Peripheral Glucagon-like Peptide-1 Receptor Signaling Differentially Regulate Addictive Behaviors","volume":"161","author":"Sirohi","year":"2016","journal-title":"Physiol. Behav."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.physbeh.2015.06.013","article-title":"The Glucagon-like Peptide 1 (GLP-1) Receptor Agonist Exendin-4 Reduces Cocaine Self-Administration in Mice","volume":"149","author":"Reddy","year":"2015","journal-title":"Physiol. Behav."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"2000","DOI":"10.1038\/s41386-018-0010-3","article-title":"Glucagon-like Peptide-1 Receptor Activation in the Ventral Tegmental Area Attenuates Cocaine Seeking in Rats","volume":"43","author":"Hernandez","year":"2018","journal-title":"Neuropsychopharmacology"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"4394","DOI":"10.1038\/s41380-020-00957-3","article-title":"GLP-1 Receptor Signaling in the Laterodorsal Tegmental Nucleus Attenuates Cocaine Seeking by Activating GABAergic Circuits That Project to the VTA","volume":"26","author":"Hernandez","year":"2021","journal-title":"Mol. Psychiatry"},{"key":"ref_61","unstructured":"(2025, April 17). An Endogenous GLP-1 Circuit Engages VTA GABA Neurons to Regulate Mesolimbic Dopamine Neurons and Attenuate Cocaine Seeking. Science Advances. Available online: https:\/\/www.science.org\/doi\/10.1126\/sciadv.adr5051."},{"key":"ref_62","doi-asserted-by":"crossref","unstructured":"Douton, J.E., Horvath, N., Mills-Huffnagle, S., Nyland, J.E., Hajnal, A., and Grigson, P.S. (2022). Glucagon-like Peptide-1 Receptor Agonist, Liraglutide, Reduces Heroin Self-Administration and Drug-Induced Reinstatement of Heroin-Seeking Behaviour in Rats. Addict. Biol., 27.","DOI":"10.1111\/adb.13117"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1038\/s41386-019-0531-4","article-title":"Activation of GLP-1 Receptors Attenuates Oxycodone Taking and Seeking without Compromising the Antinociceptive Effects of Oxycodone in Rats","volume":"45","author":"Zhang","year":"2020","journal-title":"Neuropsychopharmacology"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"104616","DOI":"10.1016\/j.neuint.2019.104616","article-title":"The Role of Linagliptin, a Selective Dipeptidyl Peptidase-4 Inhibitor, in the Morphine Rewarding Effects in Rats","volume":"133","author":"Talarek","year":"2020","journal-title":"Neurochem. Int."},{"key":"ref_65","doi-asserted-by":"crossref","unstructured":"Bornebusch, A.B., Fink-Jensen, A., W\u00f6rtwein, G., Seeley, R.J., and Thomsen, M. (2019). Glucagon-Like Peptide-1 Receptor Agonist Treatment Does Not Reduce Abuse-Related Effects of Opioid Drugs. eNeuro, 6.","DOI":"10.1523\/ENEURO.0443-18.2019"},{"key":"ref_66","doi-asserted-by":"crossref","unstructured":"Salameh, T.S., Rhea, E.M., Talbot, K., and Banks, W.A. (2020). Brain Uptake Pharmacokinetics of Incretin Receptor Agonists Showing Promise as Alzheimer\u2019s and Parkinson\u2019s Disease Therapeutics. Biochem. Pharmacol., 180.","DOI":"10.1016\/j.bcp.2020.114187"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"e133429","DOI":"10.1172\/jci.insight.133429","article-title":"Semaglutide Lowers Body Weight in Rodents via Distributed Neural Pathways","volume":"5","author":"Gabery","year":"2020","journal-title":"JCI Insight"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"D1265","DOI":"10.1093\/nar\/gkad976","article-title":"DrugBank 6.0: The DrugBank Knowledgebase for 2024","volume":"52","author":"Knox","year":"2024","journal-title":"Nucleic Acids Res."},{"key":"ref_69","unstructured":"(2025, April 18). PubChem, Available online: https:\/\/pubchem.ncbi.nlm.nih.gov\/."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1186\/s13195-024-01537-1","article-title":"Comparing Regional Brain Uptake of Incretin Receptor Agonists after Intranasal Delivery in CD-1 Mice and the APP\/PS1 Mouse Model of Alzheimer\u2019s Disease","volume":"16","author":"Abdulhameed","year":"2024","journal-title":"Alzheimer\u2019s Res. Ther."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"2583","DOI":"10.2147\/DMSO.S375559","article-title":"The Relationship Between the Blood-Brain-Barrier and the Central Effects of Glucagon-Like Peptide-1 Receptor Agonists and Sodium-Glucose Cotransporter-2 Inhibitors","volume":"15","author":"Dong","year":"2022","journal-title":"Diabetes Metab. Syndr. Obes. Targets Ther."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"E472","DOI":"10.1152\/ajpendo.00250.2023","article-title":"Brain Access of Incretins and Incretin Receptor Agonists to Their Central Targets Relevant for Appetite Suppression and Weight Loss","volume":"326","author":"Buller","year":"2024","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"e583","DOI":"10.1038\/tp.2015.68","article-title":"The Glucagon-like Peptide-1 Receptor as a Potential Treatment Target in Alcohol Use Disorder: Evidence from Human Genetic Association Studies and a Mouse Model of Alcohol Dependence","volume":"5","author":"Suchankova","year":"2015","journal-title":"Transl. Psychiatry"},{"key":"ref_74","doi-asserted-by":"crossref","unstructured":"Farokhnia, M., Browning, B.D., Crozier, M.E., Sun, H., Akhlaghi, F., and Leggio, L. (2022). The Glucagon-like Peptide-1 System Is Modulated by Acute and Chronic Alcohol Exposure: Findings from Human Laboratory Experiments and a Post-Mortem Brain Study. Addict. Biol., 27.","DOI":"10.1111\/adb.13211"},{"key":"ref_75","doi-asserted-by":"crossref","unstructured":"Quddos, F., Hubshman, Z., Tegge, A., Sane, D., Marti, E., Kablinger, A.S., Gatchalian, K.M., Kelly, A.L., DiFeliceantonio, A.G., and Bickel, W.K. (2023). Semaglutide and Tirzepatide Reduce Alcohol Consumption in Individuals with Obesity. Sci. Rep., 13.","DOI":"10.1038\/s41598-023-48267-2"},{"key":"ref_76","doi-asserted-by":"crossref","unstructured":"Tsermpini, E.E., Gori\u010dar, K., Kores Plesni\u010dar, B., Plemenita\u0161 Ilje\u0161, A., and Dol\u017ean, V. (2022). Genetic Variability of Incretin Receptors and Alcohol Dependence: A Pilot Study. Front. Mol. Neurosci., 15.","DOI":"10.3389\/fnmol.2022.908948"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"2587","DOI":"10.1038\/s41380-024-02498-5","article-title":"Association of Semaglutide with Reduced Incidence and Relapse of Cannabis Use Disorder in Real-World Populations: A Retrospective Cohort Study","volume":"29","author":"Wang","year":"2024","journal-title":"Mol. Psychiatry"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1111\/add.16679","article-title":"The Association between Glucose-Dependent Insulinotropic Polypeptide and\/or Glucagon-like Peptide-1 Receptor Agonist Prescriptions and Substance-Related Outcomes in Patients with Opioid and Alcohol Use Disorders: A Real-World Data Analysis","volume":"120","author":"Qeadan","year":"2025","journal-title":"Addiction"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"e159863","DOI":"10.1172\/jci.insight.159863","article-title":"Exenatide Once Weekly for Alcohol Use Disorder Investigated in a Randomized, Placebo-Controlled Clinical Trial","volume":"7","author":"Klausen","year":"2022","journal-title":"JCI Insight"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"e170419","DOI":"10.1172\/jci.insight.170419","article-title":"Effects of Dulaglutide on Alcohol Consumption during Smoking Cessation","volume":"8","author":"Probst","year":"2023","journal-title":"JCI Insight"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"365","DOI":"10.3390\/pharma3040025","article-title":"The Inappropriate Use of GLP-1 Analogs: Reflections from Pharmacoepidemiology","volume":"3","year":"2024","journal-title":"Pharmacoepidemiology"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"393","DOI":"10.4103\/ijp.ijp_860_22","article-title":"Translational Research: Bridging the Gap between Preclinical and Clinical Research","volume":"54","author":"Mahalmani","year":"2022","journal-title":"Indian J. Pharmacol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/S2213-8587(22)00340-0","article-title":"Pharmacogenomics of GLP-1 Receptor Agonists: A Genome-Wide Analysis of Observational Data and Large Randomised Controlled Trials","volume":"11","author":"Dawed","year":"2023","journal-title":"Lancet Diabetes Endocrinol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1111\/dom.12682","article-title":"A Missense Variant in GLP1R Gene Is Associated with the Glycaemic Response to Treatment with Gliptins","volume":"18","author":"Kvapil","year":"2016","journal-title":"Diabetes Obes. Metab."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/26\/11\/5338\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T17:45:41Z","timestamp":1760031941000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/26\/11\/5338"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,1]]},"references-count":84,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2025,6]]}},"alternative-id":["ijms26115338"],"URL":"https:\/\/doi.org\/10.3390\/ijms26115338","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,1]]}}}